Perioperative blood transfusion is associated with increased risks of tumor recurrence, metastatic progression, and cancer-related mortality.
40% of cancer diagnoses tied to extra weight; rate higher in older individuals, females.
Patients with papillary versus clear cell renal cell carcinoma have a 24% decreased risk of dying from their cancer.
In a study, partial nephrectomy was associated with a 66% lower risk for stage 4 or higher CKD versus radical nephrectomy.
The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.
Mvasi, which is approved to treat colorectal, lung, brain, kidney, and cervical cancer, was found to be biosimilar to the drug Avastin.
Checkpoint inhibitor combination of nivolumab plus ipilimumab improved progression-free and overall survival compared with sunitinib.
Cabozantinib reduced the risk of disease progression or death compared with sunitinib among patients with previously untreated advanced renal cell carcinoma.
Rises and decreases in neutrophil-to-lymphocyte ratio at 6 weeks after treatment with anti-PD-1/PD-L1 immune checkpoint blockade is associated with progression-free and overall survival.
The increased risk for obesity-related cancer was seen among women who were normal weight at enrollment.
Participant age and comorbidity burden appeared to be consistent determinants of use of services, although hospital-level variation was also noted.
Response rates of the combination therapy increasing from 20% to 40%.
The most commonly altered genes were folliculin and fumarate hydratase in 1.8% and 1.3%, respectively.
Nivolumab combined with ipilimumab revealed manageable safety, antitumor activity and favorable responses garnering potential long-term benefits.
Patients who have a complete response to 2 or more years of anti-VEGF treatment have the best progression-free and overall survival.
Both urologists and nephrologists provide follow-up and continuity of care to patients after cancer nephrectomy.
BMI and location of excess body fat on the body are good indicators of obesity-related cancer risk.
Renal and bladder cancer patients were, respectively, 77% and 73% more likely to report lifetime physical inactivity than controls without cancer.
The document spells out in greater detail the criteria for radical and partial nephrectomy and for placing patients on active surveillance.
Changes in C-reactive protein levels 4 weeks after starting sunitinib or sorafenib treatment are associated with overall and progression-free survival.
In a single-center study, 24% of patients crossed over to treatment and 95% of patients were alive after 5 years of follow-up.
Nivolumab treatment beyond disease progression results in reductions in tumor burden, study finds.
In a study, the 5-year risk of recurrence was 4.8%, 18.1%, and 46.3% for patients with low-, intermediate-, and high-risk disease.
Patients who used the drug had a 38% lower risk of dying from kidney cancer than non-users, meta-analysis shows.
World Kidney Day 2017 promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that makes preventive behaviors an affordable option.
Overall survival among patients receiving first-line targeted therapy for advanced renal cell carcinoma increased significantly from 2006 to 2012.
Study also finds associations between adiposity and 10 other cancers, particularly digestive and hormone-related malignancies.
The researchers found that patients treated with ABT had decreased progression-free survival compared with those not receiving ATB.
In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.
Added progression-free survival and prolonged overall survival possible, according to investigators.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)